Various molecules have been engineered onto the bacterial surface to increase their tropism toward tumor cells, such as tumor‐targeting peptide arginine–glycine–aspartate (RGD) bound to αvβ3 integrins and antibody fragments targeting tumor antigens like CD20 and cancer‐associated carcinoembryonic antigen (CEA).[7] Evidently, the efficient clinical translation of bacterial cancer therapy requires identification of new molecules specifically expressed in tumor tissues and development of novel modalities that target these specific markers. The gene discussed is CEACAM5; the disease is cancer.